Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02097641 · ClinicalTrials.gov registry record · Phase 2
Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)
A Phase 2 study, sponsored by Michael A. Matthay.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT02097641 is a Phase 2 study that has completed, run by Michael A. Matthay. The registered enrollment target is 60 participants.
The verdict
NCT02097641, a Phase 2 study, has completed, sponsored by Michael A. Matthay.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This was a Phase 2a, randomized, double-blind, placebo-controlled, multi-center trial to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in patients with Acute Respiratory Distress Syndrome (ARDS).
Interventions
- BIOLOGICAL Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells
- BIOLOGICAL Plasma-Lyte A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-03-15 |
| Est. Completion | 2018-02-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02097641
The ClinicalTrials.gov registry entry for NCT02097641 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Michael A. Matthay, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells is the first listed.
NCT02097641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02097641 about?
NCT02097641 is a clinical study titled "Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)". This was a Phase 2a, randomized, double-blind, placebo-controlled, multi-center trial to assess the safety and efficacy of a single dose of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) infusion in patients with Acute Respiratory Distress Syndrome (ARDS).
What is the current status of trial NCT02097641?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2014-03-15. Estimated completion is 2018-02-09.
What interventions are being tested in trial NCT02097641?
The interventions under investigation include: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells (BIOLOGICAL), Plasma-Lyte A (BIOLOGICAL).
Who is sponsoring clinical trial NCT02097641?
This trial is sponsored by Michael A. Matthay, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.